UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission file number: 001-36870 TopBuild Corp. (Exact name of Registrant as Specified in its Charter) Securities registered pursuant to Section 12 ...

Exhibit 99.1 Upstart Announces Results for Second Quarter 2025 SAN MATEO, Calif. – August 5, 2025 – Upstart Holdings, Inc. (NASDAQ: UPST), the leading artificial intelligence (AI) lending marketplace, today announced financial results for the quarter ended June 30, 2025. Upstart will host a conference call and webcast at 1:30 p.m. Pacific Time today. An earnings presentation and link to the webcast are available at ir.upstart.com. "A year ago, you saw the first signs that Upstart was returning to growth mod ...

August 5, 2025 Exhibit 99.1 Zeta Global Reports 16 th Straight "Beat and Raise" Quarter NEW YORK – Zeta Global (NYSE: ZETA), the AI Marketing Cloud, today announced financial results for the second quarter ended June 30, 2025. "We delivered another quarter of industry-leading growth, fueled by demand for our AI-powered marketing platform," said David A. Steinberg, Co-Founder, Chairman, and CEO of Zeta. "As we head into the back half of 2025, our AI-driven momentum on the heels of the Zeta Answers release, n ...

Exhibit 99.1 Financial News Release GAAP net income from continuing operations was $25.5 million or $0.67 per diluted share in the quarter, compared with $24.9 million or $0.65 per diluted share in the prior quarter, and $15.4 million or $0.41 per diluted share in the second quarter of 2024. Non-GAAP net income was $56.6 million or $1.50 per diluted share in the second quarter of 2025. This compares with $46.9 million or $1.23 per diluted share in the prior quarter, and $32.0 million or $0.85 per diluted sh ...

Exhibit 99.1 BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates - As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment - $110.6 million in total second quarter revenue, comprised of $71.5 million of U.S. Attruby® net product revenue, $1.6 million from royalty revenue, and $37.5 million in license and services ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 28, 2025 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-32833 TransDigm Group Incorporated Delaware (State or other jurisdiction of incorporation or organization) 41-2101738 (I.R.S. ...

Investor Relations: Raji Gill (949) 508-0973 Raji.Gill@skyworksinc.com Exhibit 99.1 Media Relations: Constance Griffiths (949) 230-4867 Constance.Griffiths@skyworksinc.com Revenue for the third fiscal quarter of 2025 was $965 million. On a GAAP basis, operating income for the third fiscal quarter was $111 million with diluted earnings per share of $0.70. On a non-GAAP basis, operating income was $224 million with non-GAAP diluted earnings per share of $1.33. "Skyworks delivered another strong quarter, with ...

Exhibit 99.1 Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., August 5, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2025, including sales of TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib), and recent business progress. "Ou ...